Alzex Neuropharma Inc.
TRRI
$0.10
-$0.02-16.67%
| 06/30/2011 | 03/31/2011 | 12/31/2010 | 09/30/2010 | 06/30/2010 | |
|---|---|---|---|---|---|
| Net Income | -45.48% | -118.52% | 1,444.37% | 53.54% | 57.01% |
| Total Depreciation and Amortization | 4.07% | -23.94% | 1,214.81% | -90.94% | 1,003.70% |
| Total Amortization of Deferred Charges | -- | -- | -300.37% | -- | -- |
| Total Other Non-Cash Items | 230.55% | -224.15% | -- | -100.00% | 125.55% |
| Change in Net Operating Assets | 781.02% | 124.43% | -452.50% | 86.43% | -181.99% |
| Cash from Operations | 636.45% | -131.27% | 10,900.00% | 98.77% | -374.74% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -48.07% | 186.14% | -- | -- | 222.22% |
| Total Debt Repaid | -521.05% | -126.89% | 280.00% | 19.82% | -169.70% |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -439.86% | 159.04% | -2,437.50% | -92.83% | 385.22% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 323.89% | -75.91% | 1,637.04% | 105.43% | -199.60% |
